ClinicalTrials.gov
ClinicalTrials.gov Menu

Metronomic PLD in Patients With Primary Endocrine Resistant ABC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03071926
Recruitment Status : Recruiting
First Posted : March 7, 2017
Last Update Posted : January 23, 2018
Sponsor:
Information provided by (Responsible Party):
Xichun Hu, Fudan University

Brief Summary:
Metronomic PLD in Patients with Primary Endocrine Resistant ABC

Condition or disease Intervention/treatment Phase
Advanced Breast Cancer Drug: Pegylated Liposomal Doxorubicin Phase 2

Detailed Description:
Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients with Primary Endocrine Resistant Advanced Breast Cancer

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients With Primary Endocrine Resistant Advanced Breast Cancer
Actual Study Start Date : March 1, 2017
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Pegylated Liposomal Doxorubicin
Pegylated Liposomal Doxorubicin: 20 mg, qw, first 6 weeks ,every 8 weeks
Drug: Pegylated Liposomal Doxorubicin
20 mg, qw, first 6 weeks ,every 8 weeks



Primary Outcome Measures :
  1. PFS [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]
    Progression Free Survival


Secondary Outcome Measures :
  1. Number and grade of treatment-related cardiotoxicity as assessed by CTCAE v4.0 [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]
    monitoring LVEF

  2. OS [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]
    Overall Survival

  3. CBR [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]
    Clinical Benefit Rate



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Females with age between 18 and 75 years old
  2. ECOG: 0~2
  3. Life expectancy longer than 3 months
  4. Histological proven unresectable recurrent or metastatic HR positive/HER2 negative breast cancer
  5. Primary endocrine resistance is defined as: a relapse while on the first 2 years of adjuvant ET, or PD within first 6 months of first-line ET for MBC, while on ET
  6. At least one measurable disease according to RECIST 1.1(except for bone metastasis only)
  7. LVEF ≥ 55%
  8. No radiation therapy within 4 weeks prior to enrollment
  9. Normal function of major organs: Hb ≥ 90 g/L (no blood transfusion within 14 days) ;ANC ≥1.5×109 /L;PLT ≥75×109 /L;TBIL≤1. 5×ULN; ALT、 AST≤ 3×ULN(ALT、 AST≤ 5×ULN with hepatic metastases); serum Cr ≤ 1×ULN
  10. Be willing to participate in the study, sign informed consent and cooperate with the follow-up

Exclusion Criteria:

  1. Previous accumulated or equivalent dose of doxorubicin ≥300mg/m2
  2. Intervals of anthracycline-based adjuvant chemotherapy ≤1 year (time between anthracycline-based adjuvant or neoadjuvant chemotherapy and disease relapse)
  3. Patients with symptomatic central nervous system metastases. Except for patients with stable and asymptomatic brain metastases for at least 8 weeks and no need for glucocorticoids or mannitol treatment before the trial and at least one measurable lesion outside the brain. Radiotherapy for brain metastases should be completed at least 4 weeks before the registration
  4. Pregnant or lactating women and gestational age women who are unable to use effective contraception
  5. Treatment with investigational products within 4 weeks before the study
  6. Severe cardiopulmonary insufficiency, severe hepatic and renal dysfunction
  7. Severe or uncontrolled infection
  8. Psychiatric drugs abuse and unable to withdrawal or mental disorders
  9. Other malignancies, except for cured skin basal cell carcinoma and cervical intraepithelial neoplasia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03071926


Contacts
Contact: Xichun Hu, MD, PhD 64175590 ext 85006 huxicun@gmail.com
Contact: Zhonghua Wang, MD 64175590 ext 85000 zhonghuawang95@hotmail.com

Locations
China
Fudan University Cancer Hospital Recruiting
Shanghai, China, 200032
Contact: Xichun Hu, MD,PhD    64175590 ext 85006    huxicun@gmail.com   
Contact: Zhonghua Wang, MD    64175590 ext 85000    zhonghuawang95@hotmail.com   
Sponsors and Collaborators
Fudan University
Investigators
Principal Investigator: Xichun Hu, MD, PhD Fudan University

Responsible Party: Xichun Hu, Vice Director of department of medical oncology, Fudan University
ClinicalTrials.gov Identifier: NCT03071926     History of Changes
Other Study ID Numbers: Fudan BR2017-22
First Posted: March 7, 2017    Key Record Dates
Last Update Posted: January 23, 2018
Last Verified: January 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Doxorubicin
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action